Stock Buyback Program Initiated by Elanco Animal Health (NYSE:ELAN)

Elanco Animal Health (NYSE:ELAN – Get Free Report) announced that its Board of Directors has authorized a stock repurchase program on Thursday, November 19th, RTT News reports. The company plans to repurchase $600 million in outstanding shares. This repurchase authorization permits the company to buy up to 4.5% of its stock through open market purchases. Share repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Elanco Animal Health Price Performance

Elanco Animal Health stock traded down $0.38 during midday trading on Thursday, reaching $26.32. 7,049,986 shares of the stock were exchanged, compared to its average volume of 5,428,598. Elanco Animal Health has a 52 week low of $19.40 and a 52 week high of $27.98. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.07 and a current ratio of 2.09. The firm has a market cap of $13.15 billion, a PE ratio of -87.72, a PEG ratio of 2.26 and a beta of 1.73. The company’s fifty day moving average is $23.59 and its 200-day moving average is $23.92.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its quarterly earnings results on Friday, November 6th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.20 by $0.07. The firm had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.21 billion. Elanco Animal Health had a negative net margin of 2.86% and a positive return on equity of 8.80%. The business’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period last year, the firm earned $0.19 EPS. Elanco Animal Health has set its Q4 2026 guidance at 0.160-0.190 EPS and its FY 2026 guidance at 1.170-1.200 EPS. On average, sell-side analysts forecast that Elanco Animal Health will post 1.18 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Barclays boosted their price objective on Elanco Animal Health from $30.00 to $32.00 and gave the company an “overweight” rating in a research note on Thursday. KeyCorp restated an “overweight” rating on shares of Elanco Animal Health in a research report on Monday, November 9th. JPMorgan Chase & Co. raised their price target on Elanco Animal Health from $33.00 to $35.00 and gave the stock an “overweight” rating in a report on Monday, November 9th. Weiss Ratings upgraded Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, September 4th. Finally, The Goldman Sachs Group started coverage on Elanco Animal Health in a research report on Friday, October 16th. They issued a “buy” rating and a $32.00 price target for the company. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $30.36.

Read Our Latest Research Report on Elanco Animal Health

Insider Activity

In related news, insider Timothy Bettington sold 4,350 shares of Elanco Animal Health stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $23.00, for a total transaction of $100,050.00. Following the completion of the sale, the insider owned 138,911 shares of the company’s stock, valued at approximately $3,194,953. This trade represents a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.14% of the company’s stock.

Elanco Animal Health Company Profile

(Get Free Report)

Elanco Animal Health is a global animal health company that develops, manufactures and markets products for companion animals and livestock. Its offerings include medicines, vaccines and other products intended to prevent and treat disease and support animal health. For pets, Elanco provides treatments for conditions including parasitic infections, pain and chronic diseases. Its livestock products support the health of animals such as cattle, poultry, swine and fish, serving producers and veterinarians.

Read More

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.